New drug combo aims to shrink lung tumors before surgery
NCT ID NCT06918132
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing whether giving a combination of two immunotherapy drugs (cemiplimab and fianlimab) before surgery can kill more tumor cells in people with stage IB to IIIB non-small cell lung cancer. About 60 participants will receive the drugs intravenously, then undergo surgery to remove their cancer. The main goal is to see how many patients have a major pathologic response, meaning 10% or fewer viable tumor cells remain after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cemiplimab and fianlimab (immunotherapy drugs)
- What this could lead to
- If it works, this could offer a chemotherapy-free option before lung cancer surgery, potentially improving outcomes for patients with certain PD-L1 levels.
- What could go wrong
- This is a small, early-phase trial (60 participants) with no control group. The drugs may cause immune-related side effects, and results may not apply to all lung cancer patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- Radiation hotspots may boost lung cancer treatment — a trial puts it to the test
- Could a simple assessment help older lung cancer patients tolerate chemo better?
- Could a muscle relaxant help fight lung cancer? scientists test papaverine with standard therapy
- Wheat germ supplement studied for immune boost in advanced cancer
- New drug combo shows promise for tough cancers